Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: Does it change anything?

Interactive Cardiovascular and Thoracic Surgery

Volumn 10, Issue 4, 2010, Pages 572-576

  Lucchi, Marco ^a   Picchi, Alessandro ^a   Alì, Greta ^a   Chella, Antonio ^a   Guglielmi, Giovanni ^a   Cristaudo, Alfonso ^a   Fontanini, Gabriella ^a   Mussi, Alfredo ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Chemotherapy; Immunotherapy; Mesothelioma; Multimodality treatments; Pleurectomy

Indexed keywords

CD34 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHYMASE; CISPLATIN; EPIRUBICIN; INTERLEUKIN 2; PEMETREXED; TRANSCRIPTION FACTOR FOXP3; TRYPTASE; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MAST CELL; MICROVASCULATURE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VASCULARIZATION;

ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOTHERAPY, ADJUVANT; CHYMASES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KAPLAN-MEIERS ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MAST CELLS; MESOTHELIOMA; MICROVESSELS; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PLEURAL NEOPLASMS; RADIOTHERAPY, ADJUVANT; THORACIC SURGICAL PROCEDURES; TIME FACTORS; TREATMENT OUTCOME; TRYPTASES;

EID: 77950654655     PISSN: 15699293     EISSN: None     Source Type: Journal    
DOI: 10.1510/icvts.2009.223255     Document Type: Article

References (15)

1. Treasure T, Tan C, Lang-Lazdunski L, Waller D. The MARS trial: mesothelioma and radical surgery. Interac CardioVas Thorac Surg 2006;5:58-59.
2. Martino D, Pass HI. Integration of multimodality approaches in the management of malignant pleural mesothelioma. Clin Lung Cancer 2004;5:290-298.
3. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63.
4. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620-626.
5. Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, Stahel RA. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004;22: 3451-3457.
6. Boutin C, Viallat JR, Van Zandwijk N, Douillard JT, Paillard JC, Guerin JC, Mignot P, Migueres J, Varlet F, Jehan A. Activity of intrapleural recombinant gamma interferon in malignant masothelioma. Cancer 1991;67:2033-2037.
7. Kruklitis RJ, Singhal S, Delong P, Kapoor V, Sterman DH, Kaiser LR, Albelda SM. Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg 2004;127:123-130.
8. Lucchi M, Chella A, Dini P, Melfi FMA, Ambrogi MC, Fino L, Fontanini G, Mussi A. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and longterm sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg 2007;31:529-534.
9. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon, France: IARC Press; 2004.
10. Rush VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995;108:1122-1128.
11. Alì G, Boldrini L, Lucchi M, Mussi A, Corsi V, Fontanini G. Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor. J Thorac Oncol 2009;4:348-354.
12. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-274.
13. Anraku M, Cunningham KS, Yun Z, Tsao MS, Zhang L, Keshavjee S, Johnston MR, de Perrot M. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2008;135:823-829.
14. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4q CD25(hi) Foxp3q regulatory T cells in cancer patients. Blood 2006; 107:2409-2414.
15. Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, Robinson BW, Nelson DJ. IL-2 intratumoral immunotherapy enhances CD8q T-cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol 2003; 171:5051-5063.